Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

mational," said Novavax Chief Executive Officer, Dr. Rahul Singhvi. "We eliminated 100% of our $22 million outstanding convertible debt and raised net proceeds of $21.9 million through the sale of additional shares under our ATM program. Today, Novavax has a healthy balance sheet with no long term debt and cash and short-term investments of $37.6 million as of July 31, 2009. With this financial strength, we are well positioned to advance our vaccine development programs, and in particular, continue our work on a VLP vaccine candidate against the 2009 pandemic H1N1 strain, so that we are ready to serve public health authorities in the U.S. as well as in foreign countries."

The anticipated milestones for the remainder of 2009 include:

  • Release top-line results from the Phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Initiate a Phase II clinical study of our trivalent seasonal flu vaccine in older adults;
  • Continue development of our pandemic H1N1 vaccine candidate;
  • Complete definitive license and supply agreements with ROVI; and
  • Continue expansion of operations at CPL Biologicals.

2009 Financial Results

Revenue from continuing operations for the second quarter ended June 30, 2009 was $29,000, compared to $0.3 million for the same period in 2008, a decrease of $0.3 million due to the completion of two contracts in 2009.

Research and development costs were $5.3 million for the second quarter of 2009 compared to $5.4 million in the second quarter of 2008, a decrease of $0.1 million. The decrease was due to a $0.2 million decrease in employee costs, partially offset by a $0.1 million increase in outside testing costs associated with continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by ... expected to grow at the highest CAGR of 8.46%; its growth is expected to ... and academic institutions for root cause analysis of failure. The market based on the ...
(Date:7/2/2015)... Brooklyn, NY (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in ... book style catalog to find the cuvette they needed. As expected, this was a ... would order the wrong part because they were not able to navigate the complex catalog ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( ... Orthopedics, announced today the acquisition of Turner Medical, Inc ., thus becoming ... instruments to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 /PRNewswire/ ... uses next generation sequencing technology to empower cancer care, ... as chief executive officer. In his expanded role ... for all strategy, business expansion and worldwide operations effective ... as Strand,s chairman and CEO since its founding in ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... of Standards and Technology (NIST) have been the ... into zinc oxide (ZnO) nanowires during fabrication. The ... not well-understoodrole in important optical and electrical properties ... amounts of copper. , Although zinc oxide is ...
... 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ) ... focused on researching, developing, manufacturing and,marketing biopharmaceutical products, ... as an independent director of the Company. Mr. ... since August 2006, who has,tendered his resignation as ...
... Campbell Alliance, the leading,management consulting firm specializing ... that executives from its Brand Management and,Managed ... Annual Forum on Early,Stage Product Development and ... the Center for Business Intelligence,(CBI). The conference ...
Cached Biology Technology:Chemists measure copper levels in zinc oxide nanowires 23SBio Inc. Announces Change to the Board of Directors 2Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBI's Early Commercialization Conference 2Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBI's Early Commercialization Conference 3Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBI's Early Commercialization Conference 4
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... January 17, 2014 -- The 2014 Annual Meeting of ... Forum, will kick off on January 22-25 in Davos-Klosters, ... World: Consequences for Society, Politics, and Business." Each year, ... around the world and provides an open platform to ...
... 2014 A new study exploring vitamin D levels in ... a new avenue of early intervention that may delay or ... are published in the Journal of Parkinson,s Disease . ... PD and found that higher plasma vitamin D levels were ...
... National Park Service (NPS) and outside experts, ... recommendations to conserve aerial, marine, and terrestrial populations ... U.S. national parks, often coming from distant regions of ... Conservation of Migratory Species in and out of U.S. ...
Cached Biology News:KAIST participates in the 2014 Davos Forum on Jan. 22-25 in Switzerland 2KAIST participates in the 2014 Davos Forum on Jan. 22-25 in Switzerland 3Higher vitamin D levels associated with better cognition and mood in PD patients 2National Park Service and outside experts collaborate to conserve migratory wildlife 2National Park Service and outside experts collaborate to conserve migratory wildlife 3
... 2 mM sodium phosphate buffer, pH 6.5. ... is a major lysosomal aspartyl protease in ... proenzyme. Overexpression of cathepsin D in human ... of relapse and metastasis. Cathepsin D degrades ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
Biology Products: